International Conferences

Recommended Conferences for Anti-Ageing Drugs

Anti-Ageing Drugs

---

As per available reports about 10 relevant journals, 15 Conferences, 30 workshops are presently dedicated exclusively to breathing disorder and about 2,070 articles are being published on Anti Agreing Drugs

Life extension science, also known as anti-aging medicine, indefinite life extension, experimental gerontology, and biomedical gerontology, is the study of slowing down or reversing the processes of aging to extend both the maximum and average lifespan. Some researchers in this area, and "life extensionists" or "longevists".

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance:

Anti-Ageing Drugs: There are a number of drugs intended to slow the aging process currently being researched. One type of research is related to the observed effects a calorie restriction diet, which has been shown to extend lifespan in some animals Based on that research, there have been attempts to develop drugs that will have the same effect on the aging process as a caloric restriction diet, which are known as Caloric restriction mimetic drugs. Drugs that have been studied for possible longevity effects on laboratory animals because of a possible CR-mimic effect include Rapamycin, Metformin, and Resveratrol. Two drugs that may have potential benefits of combating age-related maladies are Resveratrol and Rapamycin. These drugs are considered to be the forefront drugs in anti-aging research. Before these drugs had been tested, the best-characterized anti-aging therapy was,and still is,calorie restriction or CR. Calorie restriction has been proven to extend the life of mice,yeast, and rhesus monkeys significantly .Long-term human trials of CR are now being done.It is the hope of the anti-aging researchers that Resveratrol and Rapamycin may act as CR mimetics to increase the life span of humans. Resveratrol was first thought to be an activator of sirtuins, a family of deacetylases, that would promote anti aging effects without having to restrict caloric intake However, recent replication studies have failed to show that Resveratrol increases the life span in yeast or mice and that Resveratrol may not activate sirtuins that are biologically beneficial to age reduction. Another study was done showing that Resveratrol activates or inhibits fifteen or more different enzymes. Of those enzymes, one stands out with potential for reducing age-related disease. AMP-activated protein kinase (AMPK) has shown to increase life span of nematodes and prevent obesity in mice. Although Resveratrol has not been proven to extend the life-span of mammals at the current doses tested, Resveratrol could be used to access some of the same molecular pathways that CR does. Several examples would include diet induced obesity, some cancers, cardiovascular disease, and neurodegenerative diseases Resveratrol and Rapamycin have both shown protection against cancers, cardiovascular disease, and neurodegenerative diseases in multiple study systems. Rapamycin looks to have more potential in life span extension than Resveratrol, but my come at a price of immune system impairment. Clinical trails are now being performed to see if Rapamycin or Resveratrol will have anti-aging effects in humans. Other attempts to create anti-aging drugs have taken different research paths. One notable direction of research has been research into the possibility of using the enzyme telomerase in order to counter the process of telomere shortening. However, there are potential dangers in this, since some research has also linked telomerase to cancer and to tumor growth and formation. Current anti-aging strategies and issues: Diets and supplements: Much life extension research focuses on nutrition diets or supplements as a means to extend lifespan, although few of these have been systematically tested for significant longevity effects. The many diets promoted by anti-aging advocates are often contradictory. A dietary pattern with some support from scientific research is caloric restriction. Hormone treatments: The anti-aging industry offers several hormone therapies. Some of these have been criticized for possible dangers to the patient and a lack of proven effect. For example, the American Medical Association has been critical of some anti-aging hormone therapies Although some recent clinical studies have shown that low-dose growth hormone (GH) treatment for adults with GH deficiency changes the body composition by increasing muscle mass, decreasing fat mass, increasing bone density and muscle strength, improves cardiovascular parameters and affects the quality of life without significant side effects, the evidence for use of growth hormone as an anti-aging therapy is mixed and based on animal studies. Insulin like growth factor (IGF-1) restriction: People suffering from a rare condition known as Laron syndrome have a mutation in the gene that makes the receptor for growth hormone. It is theorised that this mutation may hold a key to life extension. Proposed strategies of life extension: Nanotechnology: Future advances in nanomedicine could give rise to life extension through the repair of many processes thought to be responsible for aging.

Market Analysis:

geographically, North America accounts for one of the largest markets followed by Europe. Baby boomers play a major role in the market growth. According to the U.S. Census Bureau, the average life expectancy in the U.S. will be 77.1 years for men and 81.9 years for women by 2020. To tackle the rising aging population, favorable reimbursement policies and extensive presence of care centers are set up to assist the problems faced by aged people. Asia Pacific is anticipated to be the fastest growing region due to the factors such as rise in persistent medical conditions and rising concern for life expectancies among the geriatric population. Latin America holds a strong potential for the market growth owing to the high presence of geriatric population and growing health care facility.

Some of the key players in this market segment are, the Jewish Family Service, the International Association of Geriatric Care, National Association of Professional Care Managers, Senior Care Centers, the UF health, the World Health Organization and others. These players constantly participate in awareness programs, as well as mergers and acquisitions to serve the elderly society effectively. 

 

List of Best International Conferences

1.      3rd European Geriatrics Congress, June 20-21, 2016, Alicantae, Spain

2.      4th Geriatrics and Gerontology conference Aug 15-17, 2016 London, UK

3.       Aging Conference, Aug 8-9, 2016 Las Vegas, USA

4.      5th Geriatric Medicine Conference Nov 17-19, 2016 Atlanta, USA

5.      4th Psychiatrist and Geriatric Psychiatry conference

6.      5th Alzheimer’s Disease and Dementia conference  September 29-October 01, 2016 London, UK

7.      2nd Conference on Sleep Disorders and Medicine conference November 28-30, 2016 Chicago, USA

8.      2nd Parkinson’s Disease and Movement Disorders conference November 28-30, 2016 Seattle, USA

9.      Rheumatology and Aging Conference 2015 08 - 11 Sep 2015,Cambridge, United Kingdom

10.  IAGG Asia/Oceania 2015 — 19- 22 Oct 2015,Chiangmai, Thailand

11.  2015 American College of Rheumatology Annual Meeting 06- 11 Nov 2015,San Francisco, United States

12.  Pro-Aging Europe Congress 2015 19 Nov -22 Nov 2015 Brussels, Belgium.

13.  Ageing 2016 09- 11 Feb 2016, London, United Kingdom.

14.  4th World Parkinson Congress (WPC 2016), September 20-23, 2016, Portland.

15.  World Congress on Active Ageing 2016, June 28/July 01/, 2016, Melbourne

16.  International Federation on Ageing - 13th Global Conference: Disasters in an Ageing World - Readiness, Resilience and Recovery, June 21-23, 2016, Brisbane.

17.  American Geriatrics Society Annual Scientific Meeting 2016, May 19-21, 2016, Long Beach

18.  American Society on Aging (ASA) 2016 Aging in America Conference, March, 2016, Washington

19.  14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy, March 20-24, 2016, Athens

20.  AGHE‘s 42nd Annual Meeting and Educational Leadership Conference, March 9-12, 2016, Long Beach

21.  Eastern Caribbean Cruise Conference 2016 - Palliative Medicine and End of Life Care: 2016 Update Including Related Topics in Neurology, February 14-21, 2016, Fort Lauderdale

Relevant Society and Associations

1.      British Geriatrics Society

2.      Canadian Geriatrics Society

3.      Geriatric society of India

4.      The Hong Kong Geriatrics Society

5.      Oregon Geriatrics Society

6.      European union Geriatric medicine society

Companies

1.      Novartis

2.      Pfizer

3.      Roche

4.      Sanofi

5.      Merck & Co.

6.      Johnson & Johnson

7.      GlaxoSmithKline

8.      AstraZeneca

9.      Gilead Sciences

10.  Takeda

11.  AbbVie

12.  Amgen

13.  Teva

14.  Lilly

15.  Bristol-Myers Squibb

16.  Bayer

17.  Novo Nordisk

18.  Astellas

19.  BoehringerIngelheim

20.  Actavis

21.  Otsuka

22.  Daiichi Sankyo

23.  Biogen Idec

24.  Baxter

25.  Merck KGaA

 

 

This page will be updated regularly.

This page was last updated on April 25, 2024